Clinical Trial Update: Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating olopatadine 0.2% for allergic conjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Olopatadine 0.2% (olopatadine hydrochloride)

Snippet

Sponsor: Alcon Research | Conditions: Allergic Conjunctivitis | Phase 3 | Status: COMPLETED